Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

HEAT-Net 2021 | The need for improved prognostic markers in Alzheimer’s disease

Although there is a good range of cerebrospinal fluid (CSF) diagnostic biomarkers, there is a need for better prognostic markers to predict Alzheimer’s disease (AD) progression as highlighted by Alberto Lleó, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. AD is often associated with co-pathologies which can impact the prognosis of the disease. Dr Lleó suggests these co-pathologies may be tracked via identification of additional biomarkers, like TDP-43 and α-synuclein. This interview took place at the Harvard European Alumni Training Network (HEAT-Net) 2021 congress.

Disclosures

Dr. Lleo has received fees for advisory board meetings from Fujirebio-Europe, Novartis, Roche Diagnostics, Otsuka Pharmaceutical, Nutricia, Zambón and Biogen, speaker honoraria from Lilly, Biogen, KRKA and Zambon and is co-author of a licensed patent on markers of synaptopathy in neurodegenerative diseases (Nº: EP18382175.0, PCT/EP2019/056535).